Comparative Pharmacology
Head-to-head clinical analysis: BINOSTO versus RISEDRONATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BINOSTO versus RISEDRONATE SODIUM.
BINOSTO vs RISEDRONATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone matrix and inhibiting farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, preventing osteoclast attachment and inducing osteoclast apoptosis.
70 mg orally once weekly
35 mg orally once weekly or 5 mg orally once daily, taken at least 30 minutes before the first food or beverage of the day with 6-8 ounces of plain water. For Paget disease: 30 mg orally once daily for 2 months.
None Documented
None Documented
Terminal elimination half-life is approximately 10 hours; clinical context: supports once-weekly dosing for osteoporosis
Terminal elimination half-life: 480 hours (20 days) due to slow release from bone; clinical context: supports once-weekly dosing for osteoporosis.
Renal: 50% excreted unchanged in urine; fecal: 20% as unabsorbed drug; biliary: negligible
Renal excretion (unchanged, via glomerular filtration and active tubular secretion): 50-65% of absorbed dose. Fecal excretion: minor, <5% as unabsorbed drug. Biliary excretion: negligible.
Category C
Category D/X
Bisphosphonate
Bisphosphonate